Shopping Cart
- Remove All
Your shopping cart is currently empty
ORIC-944 is an orally available and selective variant of PRC2 with anticancer activity for prostate cancer research.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $75 | In Stock | |
| 5 mg | $163 | In Stock | |
| 10 mg | $242 | In Stock | |
| 25 mg | $412 | In Stock | |
| 50 mg | $536 | In Stock | |
| 100 mg | $805 | In Stock |
| Description | ORIC-944 is an orally available and selective variant of PRC2 with anticancer activity for prostate cancer research. |
| In vivo | Single agent tumor growth inhibition was observed for ORIC-944 in prostate cancer xenograft models. ORIC-944 also improved ARPI antitumor activity in preclinical combination studies and demonstrated in vitro synergy. [2] |
| Synonyms | ORIC944 |
| Molecular Weight | 456.52 |
| Formula | C26H25FN6O |
| Cas No. | 2369769-29-7 |
| Smiles | N#CC=1N=C2C(=CN=C(NCC=3C(F)=CC=C4OCCC43)N2C1)C5=CC=C(C=C5C)CN(C)C |
| Color | Yellow |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80.00 mg/mL (175.24 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (7.23 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.